Bivalirudin: In patients with st-segment elevation myocardial infarction

Drugs

Volumn 70, Issue 7, 2010, Pages 909-918

  Curran, Monique P ^a  

^a Wolters Kluwer Health   (New Zealand)

Author keywords

Adis Drug Profiles; Angioplasty; Bivalirudin, general; Myocardial infarction

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; CLOPIDOGREL; EPTIFIBATIDE; HEPARIN; HIRULOG; TICLOPIDINE; TIROFIBAN;

ACUTE HEART INFARCTION; ANTICOAGULANT THERAPY; BLEEDING; CLINICAL TRIAL; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG INDICATION; DRUG METABOLISM; DRUG SAFETY; ECCHYMOSIS; HEMATOMA; HUMAN; IMMUNOGENICITY; INJECTION SITE BLEEDING; PERCUTANEOUS CORONARY INTERVENTION; REVIEW; ST SEGMENT ELEVATION; STENT THROMBOSIS; THROMBOCYTOPENIA;

BLOOD COAGULATION; CLINICAL TRIALS AS TOPIC; ELECTROCARDIOGRAPHY; HIRUDINS; HUMANS; MYOCARDIAL INFARCTION; PEPTIDE FRAGMENTS; RECOMBINANT PROTEINS; THROMBIN; TREATMENT OUTCOME;

EID: 77951740338     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11205120-000000000-00000     Document Type: Review

References (44)

1. Kushner FG, Hand M, Smith SC, et al. 2009 Focused up-dates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 Guideline and 2007 Focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2009 Dec 1, 120, 22; 2271-2306
2. Van de Werf F, Bax J, Betriu A, et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 2008 Dec; 29 (23): 2909-2945
3. Widimsky P, Wijns W, Fajadet J, et al. Reperfusion therapy for ST elevation acute myocardial infarction in Europe: description of the current situation in 30 countries. Eur Heart J. Epub 2009 Nov 19
4. De Luca G, Marino P. Antithrombotic therapies in primary angioplasty: rationale, results and future directions. Drugs 2008; 68 (16): 2325-2344
5. De Luca G, Marino P. Advances in antithrombotic therapy as adjunct to reperfusion therapies for ST-segment eleva-tion myocardial infarction. Thromb Haemost 2008 Aug; 100 (2): 184-195
6. Warkentin TE. Bivalent direct thrombin inhibitors: hirudin and bivalirudin. Best Pract Res Clin Haematol 2004 Mar; 17 (1): 105-125
7. Bittl JA, Chaitman BR, Feit F, et al. Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: final report reanalysis of the Bivalirudin Angioplasty Study. Am Heart J 2001 Dec; 142 (6): 952-959
8. Lincoff AM, Bittl JA, Harrington RA, et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 2003 Feb 19; 289 (7): 853-863
9. Stone GW, White HD, Ohman EM, et al. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial. Lancet 2007 Mar 17; 369 (9565): 907-919
10. Stone GW, Witzenbichler B, Guagliumi G, et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 2008 May 22; 358 (21): 2218-2230
11. Rassen JA, Mittleman MA, Glynn RJ, et al. Safety and ef-fectiveness of bivalirudin in routine care of patients undergoing percutaneous coronary intervention. Eur Heart J 2010 Mar; 31 (5): 561-572
12. The Medicines Company. Summary of product character-istics: Angiox (bivalirudin). Oxfordshire: The Medicines Company 2009 Nov 20
13. Deeks ED, Curran MP. Bivalirudin: in patients with acute coronary syndromes planned for urgent or early intervention. Drugs 2008; 68 (16): 2345-2356
14. Moen MD, Keating GM, Wellington K. Bivalirudin: a re-view of its use in patients undergoing percutaneous coronary intervention. Drugs 2005; 65 (13): 1869-1891
15. The Medicines Company. Angiomax® (bivalirudin) for injection: US prescribing information [online]. Available from URL: http://www.angiomax.com [Accessed 2010 Feb 1]
16. Weitz JI, Hudoba M, Massel D, et al. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990 Aug; 86 (2): 385-391
17. Nappi J. The biology of thrombin in acute coronary syn-dromes. Pharmacotherapy 2002; 22 (6 Pt 2): 90S-6S
18. Nylander S, Mattsson C. Thrombin-induced platelet acti-vation and its inhibition by anticoagulants with different modes of action. Blood Coagul Fibrinolysis 2003 Feb; 14 (2): 159-167
19. Leger AJ, Jacques SL, Badar J, et al. Blocking the protease-activated receptor 1-4 heterodimer in platelet-mediated thrombosis. Circulation 2006 Mar 7; 113 (9): 1244-1254
20. Anand SX, Kim MC, Kamran M, et al. Comparison of platelet function and morphology in patients undergoing percutaneous coronary intervention receiving bivalirudin versus unfractionated heparin versus clopidogrel pretreatment and bivalirudin. Am J Cardiol 2007 Aug 1; 100 (3): 417-424
21. Keating FK, Dauerman HL, Whitaker DA, et al. Increased expression of platelet P-selectin and formation of platelet-leukocyte aggregates in blood from patients treated with unfraction ated heparin plus eptifibatide compared with bivalirudin. Thromb Res 2006; 118 (3): 361-369
22. Schneider DJ, Keating F, Sobel BE. Greater inhibitory effects of bivalirudin compared with unfractionated heparin plus eptifibitide on thrombin-induced platelet activation. Coron Artery Dis 2006 Aug; 17 (5): 471-476
23. Schneider DJ, Sobel BE. Lack of early augmentation of platelet reactivity after coronary intervention in patients treated with bivalirudin. J Thromb Thrombolysis 2009 Jul; 28(1): 6-9
24. Ray MJ, Juneja M, Bett N, et al. A comparison of anti coagulation with bivalirudin and provisional GPIIb/IIIa inhibition with unfractionated heparin and mandatory GPIIb/IIIa inhibition during percutaneous coronary intervention in relation to platelet activation and the inhibition of coagulation. EuroIntervention 2009 Aug; 5 (3): 330-335
25. Busch G, Steppich B, Sibbing D, et al. Bivalirudin reduces platelet and monocyte activation after elective percutaneous coronary intervention. Thromb Haemost 2009 Feb; 101 (2): 340-344
26. Sibbing D, Busch G, Braun S, et al. Impact of bivalirudin or unfractionated heparin on platelet aggregation in patients pretreated with 600 mg clopidogrel undergoing elective percutaneous coronary intervention. Eur Heart J 2008 Jun; 29(12): 1504-1509
27. Kleiman NS, Klem J, Fernandes LS, et al. Pharmacodyna-mic profile of the direct thrombin antagonist bivalirudin given in combination with the glycoprotein IIb/IIIa antagonist eptifibatide. Am Heart J 2002 Apr; 143 (4): 585-593
28. Harding SA, Din JN, Sarma J, et al. Promotion of proin-flammatory interactions between platelets and monocytes by unfractionated heparin. Heart 2006 Nov; 92(11): 1635-1638
29. Bates ER. Bivalirudin: an anticoagulant option for percu-taneous coronary intervention. Expert Rev Cardiovasc Ther 2004 Mar; 2 (2): 153-162
30. Fox I, Dawson A, Loynds P, et al. Anticoagulant activity of hirulog™, a direct thrombin inhibitor, in humans. Thromb Haemost 1993 Feb 1; 69 (2): 157-163
31. Topol EJ, Bonan R, Jewitt D, et al. Use of a direct anti-thrombin, hirulog, in place of heparin during coronary angioplasty. Circulation 1993 May; 87 (5): 1622-1629
32. Cannon CP, Maraganore JM, Loscalzo J, et al. Anti-coagulant effects of hirulog, a novel inhibitor, in patients with coronary artery disease. Am J Cardiol 1993 Apr 1; 71 (10): 778-782
33. Robson R, White H, Aylward P, et al. Bivalirudin pharm-acokinetics and pharmacodynamics: effect of renal function, dose, and gender. Clin Pharmacol Ther 2002 Jun; 71 (6): 433-439
34. Lincoff AM, Bittl JA, Kleiman NS, et al. Comparison of bivalirudin versus heparin during percutaneous coronary intervention (the randomized evaluation of PCI Linking Angiomax to reduced Clinical Events [REPLACE]-1 trial). Am J Cardiol 2004 May 1; 93 (9): 1092-1096
35. Carswell CI, Plosker GL. Bivalirudin: a review of its poten-tial place in the management of acute coronary syndromes. Drugs 2002; 62 (5): 841-870
36. Stella J, Stella R, Stella D, et al. The bivalirudin in the management of patients with ST-segment elevation acute myocardial infarction undergoing primary PCI (BIAMI) trial: in-hospital, 30-day, and 6-month results [abstract no. A-34]. Cathet Cardiovasc Interv 2006; 67: 751. Plus poster presented at the 29th Annual Scientific Sessions of the Society for Cardiovascular Angiography and Interventions; 2006 May 10-13; Chicago (IL)
37. Mehran R, Lansky AJ, Witzenbichler B, et al. Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial. Lancet 2009 Oct 3; 374 (9696): 1149-1159
38. Stone GW, for the HORIZONS-AMI Investigators. HOR-IZONS AMI: two-year follow-up from a prospective randomized trial of heparin plus glycoprotein IIb/IIIa inhibitors vs. bivalirudin and paclitaxel-eluting vs. bare-metal stents in STEMI [abstract plus oral presentation]. 21st Annual Scientific Symposium on Transcatheter Cardiovascular Therapeutics; 2009 Sep 21-26; San Francisco (CA)
39. Dudek D, Zmudka K, Witzenbichler B, et al. Impact of ad-vanced age on the safety and effectiveness of bivalirudin in patients with acute myocardial infarction undergoing primary angioplasty: the HORIZONS AMI trial [abstract no. 2900-191]. J Am Coll Cardiol 2008; 51 Suppl. 2 (10): B67
40. Grinfeld L, Belardi J, Lansky A, et al. Impact of gender on the safety and effectiveness of bivalirudin in patients with acute myocardial infarction undergoing primary angioplasty: the HORIZONS-AMI trial [abstract no. 2900-194]. J Am Coll Cardiol 2008 Mar 11; 51 Suppl. 2 (10): B67
41. European Medicines Agency. Angiox-H-562-II-24 assess-ment report [online]. Available from URL: http://www. ema. europa.eu/humandocs/PDFs/EPAR/ angiox/Angiox-H-5 62-II-24-AR.pdf [Accessed 2010 Apr 1]
42. Sejersten M, Nielsen SL, Engstrom T, et al. Feasibility and safety of prehospital administration of bivalirudin in patients with ST-elevation myocardial infarction. Am J Cardiol 2009 Jun 15; 103 (12): 1635-1640
43. The Medicines Company. European ambulance acute cor-onary syndrome angiox trial (EUROMAX): clinical study protocol TMC-BIV-08-103 [online]. Available from URL: http://www.sfcardio.fr/cnchg/recherche-clinique/bourse-des../euromax.. /file [Accessed 2010 Feb 10]
44. US National Institutes of Health. Utilisation of Angiox® in European Practice (EURO-vision) [ClinicalTrials.gov identifier NCT01011504]. US National Institutes of Health, Clinical.Trials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2010 Feb 10]